[ad_1]
Steven M. Lipkin, MD, Ph.D., Professor of Medicine Gladys and Roland Harriman, Professor of Medicine at the Division of Gastroenterology and Hepatology, Vice President of Research at the Department of Medicine at Weill Cornell Medicine; and a geneticist from NewYork-Presbyterian / Weill Cornell Medical Center, discuss a study of a preventive cancer vaccine in a preclinical model of Lynch syndrome at the 2019 AACR annual meeting .
The researchers evaluated a neo-antigen vaccine in mouse models that developed Lynch syndrome to determine safety and effectiveness before testing it in humans. The key concept is that Lynch syndrome mutation rates are so high that patients develop exactly the same mutations as tumors, says Lipkin.
Vaccination with as few as 4 tumor antigens generated antigen-specific responses, reduced intestinal tumors, and improved survival in the murine model. In addition, the combination of vaccination and naproxen significantly improved the overall survival of mice with Lynch syndrome compared with vaccination alone. Overall survival was 541 days compared to 380 days in mice treated with the vaccine alone.
The investigators are considering a system in which, in the future, there will be a library of peptides and a preliminary badysis of the patient's immune history. The peptides would then be mixed with adjuvants that stimulate the immune system, leading to an attack of T cells. According to Lipkin, the next steps in this research are to identify an optimal peptide system, the type of adjuvant to be used and the number of injections to administer. Then, the researchers will conduct a first study in humans to badess the safety and determine if the immune systems are activated against these mutations.
<<< Annual Meeting of the AACR 2019
Source link
